Andreessen Horowitz backs a new molecule builder from UCLA equipped with the latest in convergence tech. And he’s aiming big
Sri Kosuri has spent years at a scientific crossroads, watching the rapidly accelerating work on synthetic biology, big data and genomics. The MIT grad spent time working as a staff scientist with George Church at the Wyss Institute. And he kept at it as a professor in chemistry at UCLA.
Now, Kosuri’s taken a leave of absence after bagging a $30 million investment from Andreessen Horowitz to see if he can take these convergent technologies in polypharmacology and create a powerful new machine for drug discovery. The upstart biotech is called Octant. And Kosuri’s shooting for something groundbreaking in the toughest fields he can find.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.